NO880022L - Fremstilling av m-csf. - Google Patents

Fremstilling av m-csf.

Info

Publication number
NO880022L
NO880022L NO880022A NO880022A NO880022L NO 880022 L NO880022 L NO 880022L NO 880022 A NO880022 A NO 880022A NO 880022 A NO880022 A NO 880022A NO 880022 L NO880022 L NO 880022L
Authority
NO
Norway
Prior art keywords
csf
preparation
enclosed
defects
protein
Prior art date
Application number
NO880022A
Other languages
English (en)
Other versions
NO880022D0 (no
Inventor
Steven C Clark
Gordon G Wong
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/860,377 external-priority patent/US4879227A/en
Priority claimed from US06/940,362 external-priority patent/US4868119A/en
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of NO880022D0 publication Critical patent/NO880022D0/no
Publication of NO880022L publication Critical patent/NO880022L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En ny prosedyre for fremstilling av humant M-CSF er vedlagt. Proteinet benyttes ved behandling av forstyr- relser karakterisert ved mangler i hematopoletlske celler.
NO880022A 1986-05-06 1988-01-05 Fremstilling av m-csf. NO880022L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/860,377 US4879227A (en) 1986-05-06 1986-05-06 Production of a recombinant human colony stimulating factor
US06/940,362 US4868119A (en) 1986-12-11 1986-12-11 Hematopoietic growth factors
PCT/US1987/000835 WO1987006954A1 (en) 1986-05-06 1987-04-13 Production of m-csf

Publications (2)

Publication Number Publication Date
NO880022D0 NO880022D0 (no) 1988-01-05
NO880022L true NO880022L (no) 1988-01-05

Family

ID=27127565

Family Applications (1)

Application Number Title Priority Date Filing Date
NO880022A NO880022L (no) 1986-05-06 1988-01-05 Fremstilling av m-csf.

Country Status (21)

Country Link
US (1) US5573763A (no)
EP (1) EP0307402B1 (no)
JP (2) JP2579981B2 (no)
KR (1) KR960004453B1 (no)
AT (1) ATE92966T1 (no)
AU (1) AU606056B2 (no)
CA (1) CA1334942C (no)
DE (1) DE3787020T2 (no)
DK (1) DK2688A (no)
ES (1) ES2007341A6 (no)
FI (1) FI884877A (no)
GR (1) GR870688B (no)
HU (1) HU212277B (no)
IE (1) IE60835B1 (no)
IL (1) IL82400A0 (no)
MX (1) MX9203130A (no)
MY (1) MY101209A (no)
NO (1) NO880022L (no)
OA (1) OA09112A (no)
PH (1) PH24301A (no)
WO (1) WO1987006954A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146851A (en) * 1985-02-05 2000-11-14 Chiron Corporation DNA encoding NV2 (long form) and carboxy truncated fragments thereof
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US6156300A (en) * 1985-02-05 2000-12-05 Chiron Corporation Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
EP0209601B1 (en) * 1985-02-05 1993-12-15 Cetus Oncology Corporation Recombinant colony stimulating factor-1
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
US4808611A (en) * 1986-07-30 1989-02-28 Immunex Corporation Use of interleukin-1 to induce development of multipotent hemopoietic cell populations
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
JP2583829B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 ヒトｍ−ｃｓｆ
US5650297A (en) * 1986-09-17 1997-07-22 Otsuka Pharmaceutical Co., Ltd. DNA encoding human colony-stimulating factors
JPH07100720B2 (ja) * 1987-07-17 1995-11-01 森永乳業株式会社 コロニー刺激因子の製造法
CA1339757C (en) 1987-04-16 1998-03-17 Robert F. Halenbeck Production of purified biologically active, bacterially produced recombinant human csf-1
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
EP0643972B1 (en) * 1987-09-22 2002-03-06 Chiron Corporation Use of recombinant colony stimulating factor-1 for the preparation of a medicament for cytomegalovirus infections
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
DK54589A (da) * 1988-02-08 1989-08-09 Otsuka Pharma Co Ltd Humane kolonistmulerende faktorer
JPH0610137B2 (ja) * 1988-02-29 1994-02-09 新技術事業団 ヒト単球−マクロファージコロニー刺激因子を有効成分とする造血器疾患治療剤
KR900700156A (ko) * 1988-04-27 1990-08-11 원본미기재 개선된 방사선 치료법
US5888495A (en) * 1988-05-23 1999-03-30 Genetics Institute, Inc. Method of producing storage stable M-CSF lyophilizates
US5171675A (en) * 1988-07-28 1992-12-15 Cerretti Douglas P Macrophage colony stimulating factor-γ
JPH0651640B2 (ja) * 1989-01-30 1994-07-06 シェリング・コーポレーション Ｇｍ―ｃｓｆを用いる白血球機能障害の治療
DK0457804T3 (da) * 1989-02-10 1996-09-23 Chiron Corp M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
AU625081B2 (en) * 1989-02-28 1992-07-02 Morinaga Milk Industry Company Limited Human monocyte-macrophage-csf preparations
US5288487A (en) * 1989-02-28 1994-02-22 Morinaga Milk Industry Co., Ltd. Human monocyte-macrophage-CSF preparations
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
DE69026440T2 (de) * 1989-07-27 1996-10-17 Denki Kagaku Kogyo Kk Für M-CSF kodierendes Gen und dazu gehörende rekombinante Systeme
WO1994016075A2 (en) * 1993-01-13 1994-07-21 Genetics Institute, Inc. Process for producing m-csf 223
ATE386811T1 (de) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
US6455678B1 (en) * 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
ATE299030T1 (de) * 1996-07-10 2005-07-15 Meiji Dairies Corp Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
EP2089049A4 (en) * 2006-11-17 2011-11-16 Biogen Idec Inc SYSTEMIC ADMINISTRATION OF COLONIAL STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISEASES
WO2024017998A1 (en) 2022-07-21 2024-01-25 Technische Universität Dresden M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression
EP4309666A1 (en) 2022-07-21 2024-01-24 Technische Universität Dresden M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784949A (en) * 1984-04-19 1988-11-15 Cetus Corporation Universal dominant selectable marker cassette
EP0211899B1 (en) * 1985-02-05 1992-09-23 Cetus Oncology Corporation Purification of native colony stimulating factor-1
EP0209601B1 (en) * 1985-02-05 1993-12-15 Cetus Oncology Corporation Recombinant colony stimulating factor-1
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
JP2644794B2 (ja) * 1986-10-24 1997-08-25 カイロン コーポレイション 新規な型のコロニー刺激因子―１

Also Published As

Publication number Publication date
DE3787020D1 (de) 1993-09-16
DK2688D0 (da) 1988-01-05
DK2688A (da) 1988-03-07
IL82400A0 (en) 1987-11-30
DE3787020T2 (de) 1993-12-16
IE870994L (en) 1987-11-06
JPH01502397A (ja) 1989-08-24
FI884877A0 (fi) 1988-10-21
GR870688B (en) 1987-09-07
WO1987006954A1 (en) 1987-11-19
OA09112A (en) 1991-10-31
HU212277B (en) 1996-04-29
FI884877A (fi) 1988-10-21
JP2579981B2 (ja) 1997-02-12
AU606056B2 (en) 1991-01-31
NO880022D0 (no) 1988-01-05
US5573763A (en) 1996-11-12
MX9203130A (es) 1992-07-01
EP0307402A4 (en) 1990-02-22
ES2007341A6 (es) 1989-06-16
AU7289087A (en) 1987-12-01
EP0307402A1 (en) 1989-03-22
PH24301A (en) 1990-05-29
ATE92966T1 (de) 1993-08-15
KR960004453B1 (en) 1996-04-06
HUT47979A (en) 1989-04-28
CA1334942C (en) 1995-03-28
JPH07147989A (ja) 1995-06-13
IE60835B1 (en) 1994-08-24
KR880701288A (ko) 1988-07-26
MY101209A (en) 1991-08-17
EP0307402B1 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
NO880022L (no) Fremstilling av m-csf.
NO844054L (no) Fremgangsmaate for fremstilling av terapeutisk aktive hyaluronsyre-fraksjoner
NO162613C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive diarylacetylener.
NO874869L (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
DK173883D0 (da) Substituerede 8-phenylxanthiner
AU8240687A (en) Preparation suitable for use in the treatment of enteric disorders
NO159528C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive aminoguanidinderivater.
DK496687A (da) Anvendelse af medetomidin til fremstilling af laegemiddel til brug ved behandling af angstsygdomme
EP0178443A3 (en) Soaps and shampoos containing bioemulsifiers
NO162557C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive (pyrrol-1-yl)-fenyldihydropyridazinoner.
NO831775L (no) Fremgangsmaate for fremstilling av fermentert myse
EP0241889A3 (de) Verwendung von TNF zur Herstellung von Arzneimitteln
IT7967029A0 (it) Amminoderivati della pirazolo i 5 as triazina particolarmente utili in terapia e procedimento per la loropreparazione
IT1133044B (it) Procedimento per la riduzione della stabilita' termica del caglio microbico
IT1173473B (it) Procedimento per la preparazione di 1,8-diidrossi-10-acil-9-antroni,in particolare per l'uso nel trattamento di psoriasi
NO164417C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive iminothiazolidinderivater.
SE8404334L (sv) 16-fluoro-16,17-didehydro-prostanoider och forfarande for deras framstellning
ZA874470B (en) New tetrahydrobenzothiazoles,and the preparation and use thereof
IT7967130A0 (it) Rivati del 5 fenetil 2 ossazolidone ne e procedimento per la loro preparazione
NO170012C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzamider
AU5184286A (en) Treatment of biomass with steam
PT85278A (fr) Procede de preparation d:une fraction immunogene active a liegard des bilharzioses et de compositions immunisantes la contenant
TR24449A (tr) Tiyazinol tuerevleri hazirlanmalarina mahsus usul v ve fungusid olarak kullanimi
NO168581C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive beta-methylen-thiofenethanaminer
ES545117A0 (es) Procedimiento de preparacion de nuevos derivados de acido- 9- u 11-nitroaprovincaminico racemicos y opticamente activos